title: In vitro leukemia cell models of Ara-C resistance.
abstract: Cells of the human leukemia line K562 were continuously exposed to cytosine arabinoside (Ara-C) at increasing concentrations for 3 months. The resulting cell line, termed K562/AC, showed 48-fold resistance to Ara-C, compared with the parental K562 cells. The sensitivities of K562/AC to adriamycin (ADR), vincristine (VCR) and etoposide (VP16) were similar to those of parental K562. Gene analysis revealed that this cell line lacked expression of the deoxycytidine kinase (dCK) gene, which was evident in Ara-C-sensitive cells. As in K562 cells, multidrug resistance (MDR-1) and multidrug resistance protein (MRP) genes were not expressed in K562/AC. We also established an in vitro model of Ara-C resistance using phosphorothioate antisense oligonucleotides to dCK (dCK-AS). Treatment of K562 with dCK-AS caused decreased dCK expression and 6- to 10-fold increases in resistance to Ara-C, compared with that in cells treated with sense oligonucleotides to dCK (dCK-S) or in non-transfected cells. The cells described here may contribute to the study of a novel mechanism associated with Ara-C resistance, in which reduced dCK activity may play an important role.
authors.affiliation: Department of Molecular Genetics, School of Medicine, Tohoku University, Seiryoumachi 1-1, Aoba-ku, Sendai, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Funato
authors.forename: J
authors.initials: J
authors.lastname: Satou
authors.forename: Y
authors.initials: Y
authors.lastname: Nishiyama
authors.forename: S
authors.initials: S
authors.lastname: Fujimaki
authors.forename: T
authors.initials: T
authors.lastname: Miura
authors.forename: M
authors.initials: M
authors.lastname: Kaku
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
chemical_list: D000964:Antimetabolites, Antineoplastic; D020319:Oligodeoxyribonucleotides, Antisense; D003561:Cytarabine